Sale of bioMérieux Australia's Clinical PPM business22 January, 2019
bioMérieux Australia announces today the sale to Edwards Group, of its clinical microbiology culture media business in Australia and New Zealand.
bioMérieux will continue operating the culture business as normal, until Edwards takes full ownership after a two month transition period.
All orders and customer enquiries should continue to be directed to bioMérieux Australia per usual channels until further notice. Further information will be provided over the coming months.
This sale announced today supports bioMérieux Australia's strategy to focus on providing advanced solutions for infectious disease management in the Australia and New Zealand healthcare systems.
The sale of bioMérieux Australia's Clinical PPM business secures a strong domestic partner to ensure bioMérieux's Australia and New Zealand customers continue to have access to bioMérieux's PPM products. The sale also secures the future of the bioMérieux PPM manufacturing operations located in Brisbane.
Edwards Group is a leading supplier of laboratory equipment and consumables including the manufacture of PPM products to laboratories performing microbiological testing in Australia and New Zealand, operating under both the Edwards Group and Fort Richard brands. Edwards Group has access to five decades of experience in the manufacture of PPM and supplies a wide range of specialist microbiology consumables and equipment including prepared culture media.
Under the sale agreement, Edwards will partner with bioMérieux for the Australia and New Zealand rights for all bioMérieux culture products produced in Brisbane, along with imported ChromlD culture products for use in clinical microbiology.
bioMérieux Australia will continue to sell imported culture products to industrial microbiology customers.
Making the announcement, Executive Vice President Asia Pacific for bioMérieux Pierre Boulud said, "bioMérieux is excited to be working with Edwards Group and we will help ensure a smooth transition of the Clinical PPM Manufacturing business over the coming months. We are also looking forward to further focusing our business priorities around providing advanced diagnostics solutions for infectious disease management"
Edwards Group Managing Director Richard Clist also said on announcing the sale, "We are looking forward to expanding our business further through the purchase of the bioMérieux Clinical PPM business. This acquisition is closely aligned with our core business / capabilities and will help us further deliver high quality solutions and services to microbiology laboratories across Australia and New Zealand".
bioMérieux is a world leader in the field of in vitro diagnostics for over 50 years, bioMérieux is present in more than 150 countries through 43 subsidiaries and a large network of distributors. In 2017, revenues reached €2.3 billion, with over 90% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
Edwards Group was first established in 1961 and has since moved from strength to strength through its commitment to quality, service and innovation. Edwards Group is now among Australasia's largest manufacturers of prepared culture media and offer a wide range of specialist microbiology consumables and equipment in the region.
Executive VP, Head of Asia Pacific Region- Portfolio & Strategic Planning